Categories
Change Password!
Reset Password!
Subcutaneous Tocilizumab provides sustained disease control and a favourable safety profile for enhancing quality of life and improving the management of juvenile idiopathic arthritis.
According to a study published in the Journal of Pediatric Urology, patients suffering from polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA) experienced remarkable disease control with the use of Tocilizumab administered subcutaneously (SC).
The study, conducted as a long-term extension (LTE) of clinical trials, aimed to explore the safety and efficacy of Tocilizumab SC treatment for patients with pJIA or sJIA. Patients who demonstrated adequate response during the initial 52-week phase 1b core trials were enrolled in the LTE, where they continued to receive Tocilizumab subcutaneous treatment for up to 5 years or until commercial availability.
Among the participants (44 patients with pJIA; 38 patients with sJIA), Tocilizumab maintained trough concentrations within the expected range for optimal clinical benefit over 3 years. Additionally, key pharmacodynamic parameters remained stable throughout the LTE, aligning with levels achieved during the core trials. A significant portion of patients achieved inactive disease status as per the American College of Rheumatology provisional criteria, showcasing the efficacy of Tocilizumab in managing JIA. Six patients with pJIA and five patients with sJIA reported serious adverse events.
Journal of Pediatric Urology
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keae180/7637686
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis
Hermine I Brunner et al.
Comments (0)